{"protocolSection":{"identificationModule":{"nctId":"NCT05525949","orgStudyIdInfo":{"id":"NNS-VB-02"},"organization":{"fullName":"Nunaps Inc","class":"INDUSTRY"},"briefTitle":"Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke","officialTitle":"Treatment of Homonymous Visual Loss With Digital Therapeutics, VIVID Brain, Visual Perceptual Learning Device (HOGWAND Trial) : Multi Center, Randomized, Single-blind (Evaluator), Superiority Prove, Prospective Confirmatory Trial"},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-10-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-08-11","type":"ACTUAL"},"completionDateStruct":{"date":"2023-11-08","type":"ACTUAL"},"studyFirstSubmitDate":"2022-08-31","studyFirstSubmitQcDate":"2022-08-31","studyFirstPostDateStruct":{"date":"2022-09-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-11-09","lastUpdatePostDateStruct":{"date":"2023-11-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Nunaps Inc","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain disease. Half of participants will receive visual perceptual training using the VIVID Brain. The other half will not receive any training because there is no standard treatment for visual field defect caused by brain disease."},"conditionsModule":{"conditions":["Visual Fields Hemianopsia","Hemianopsia, Homonymous"],"keywords":["Visual field defect","Visual perceptual learning","Humphrey visual field"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":93,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"VIVID Brain","type":"EXPERIMENTAL","description":"VIVID Brain, 5 times a week for 12 weeks","interventionNames":["Device: VIVID Brain"]},{"label":"No-treatment Control","type":"OTHER","description":"No-treatment is administered during control period.","interventionNames":["Other: No-treatment Control"]}],"interventions":[{"type":"DEVICE","name":"VIVID Brain","description":"Participants receive visual perceptual training using the VIVID Brain software.","armGroupLabels":["VIVID Brain"]},{"type":"OTHER","name":"No-treatment Control","description":"No-treatment is administered during control period.","armGroupLabels":["No-treatment Control"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The sum of improved areas compared to baseline in the whole field","description":"The sum of areas where sensitivity increased by more than 6 dB compared to baseline in the whole field measured by Humphrey visual field test.\n\nThe improved area ranges between 0 and 2,736 degree\\^2, of which larger area indicates better outcome.","timeFrame":"12 weeks"}],"secondaryOutcomes":[{"measure":"The sum of improved areas compared to baseline in the affected hemi-field","description":"The sum of areas where sensitivity increased by more than 6 dB compared to baseline in the affected hemi-field measured by Humphrey visual field test.","timeFrame":"12 weeks"},{"measure":"Changes in perimetric mean deviation relative to baseline in the whole field","description":"Changes in perimetric mean deviation relative to baseline in the whole field measured by Humphrey visual field test.","timeFrame":"12 weeks"},{"measure":"Changes in mean total deviation relative to baseline in the affected hemi-field","description":"Changes in mean total deviation relative to baseline in the affected hemi-field measured by Humphrey visual field test.","timeFrame":"12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 19 years and older\n* At least 3 months after brain disease related to visual field defect\n* Verified brain disease in visual pathway related to occipital lobe, parietal lobe, temporal lobe or etc. using CT or MRI\n* Brain disease induced visual field defect\n* Able to use the VR(Virtual Reality) device\n* Able to use the app with a smart phone\n* Patient/legally authorized representative has signed the informed consent form\n\nExclusion Criteria:\n\n* Complete hemianopsia\n* Epilepsy, photosensitivity, Parkinson's disease\n* Bilateral visual field defect\n* Hemispatial neglect\n* Ophthalmologic disorder that may interfere the trial. (Ptosis of Eyelid, Corneal Opacity, Diabetic Retinopathy, Glaucoma, Macular Degeneration etc.)\n* Inability to discontinue psychostimulants such as methylphenidate, modafinil, and amphetamine.\n* Candidate for carotid endarterectomy or stenting\n* Received ophthalmologic surgery or laser surgery within 3 months, except for the cataract surgery\n* Pregnant or breast feeding\n* Participating in other clinical trial\n* Any other condition that, in the opinion of the investigator, precludes participation in the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Gyeong-Moon Kim, MD, PhD","affiliation":"Samsung Medical Center","role":"STUDY_CHAIR"}],"locations":[{"facility":"Korea University Ansan Hospital","city":"Ansan","country":"Korea, Republic of","geoPoint":{"lat":37.32361,"lon":126.82194}},{"facility":"Hallym University Sacred Heart Hospital","city":"Anyang","country":"Korea, Republic of","geoPoint":{"lat":37.3925,"lon":126.92694}},{"facility":"Daejeon Eulji University Medical Center","city":"Daejeon","country":"Korea, Republic of","geoPoint":{"lat":36.32139,"lon":127.41972}},{"facility":"Inje University Ilsan Paik Hospital","city":"Goyang","country":"Korea, Republic of","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam","country":"Korea, Republic of","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Asan Medical Center","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Chung-Ang University Hospital","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Konkuk University Hospital","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"The Catholic University of Korea Seoul St. Mary's Hospital","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"The Catholic University of Korea Yeouido St. Mary's Hospital","city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ulsan University Hospital","city":"Ulsan","country":"Korea, Republic of","geoPoint":{"lat":35.53722,"lon":129.31667}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000006423","term":"Hemianopsia"}],"ancestors":[{"id":"D000014786","term":"Vision Disorders"},{"id":"D000012678","term":"Sensation Disorders"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000001766","term":"Blindness"},{"id":"D000005128","term":"Eye Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9199","name":"Hemianopsia","asFound":"Hemianopsia","relevance":"HIGH"},{"id":"M17220","name":"Vision Disorders","relevance":"LOW"},{"id":"M15180","name":"Sensation Disorders","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M4737","name":"Blindness","relevance":"LOW"},{"id":"M7961","name":"Eye Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC11","name":"Eye Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M5953","name":"Coal Tar","relevance":"LOW"}],"browseBranches":[{"abbrev":"Derm","name":"Dermatologic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}